The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
1-(4-(4-(((2r,5r)-2-((1H-imidazol-1-yl)methyl)-2-(2-chlorophenyl)-1,3-dioxan-5-yloxy)methyl)phenyl)piperazin-1-yl)ethanone ID: ALA4285744
Max Phase: Preclinical
Molecular Formula: C27H31ClN4O4
Molecular Weight: 511.02
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: CC(=O)N1CCN(c2ccc(CO[C@H]3CO[C@@](Cn4ccnc4)(c4ccccc4Cl)OC3)cc2)CC1
Standard InChI: InChI=1S/C27H31ClN4O4/c1-21(33)31-12-14-32(15-13-31)23-8-6-22(7-9-23)16-34-24-17-35-27(36-18-24,19-30-11-10-29-20-30)25-4-2-3-5-26(25)28/h2-11,20,24H,12-19H2,1H3/t24-,27+
Standard InChI Key: KXAVEJVPHQCMQP-FEGDYQJNSA-N
Molfile:
RDKit 2D
36 40 0 0 0 0 0 0 0 0999 V2000
33.4063 -6.6540 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.4052 -7.4814 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.1200 -7.8942 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.8365 -7.4809 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.8335 -6.6503 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.1182 -6.2413 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.6925 -6.2419 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
32.6943 -5.4159 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
31.9838 -5.0037 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.2670 -5.4128 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.2653 -6.2387 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.9803 -6.6556 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
32.6869 -7.0666 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.9698 -7.4742 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.2170 -7.1390 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.6608 -7.7483 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
31.0685 -8.4655 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
31.8766 -8.2994 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
30.5541 -4.9978 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
29.8381 -5.4078 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.1252 -4.9928 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.1315 -4.1679 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.4193 -3.7529 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.7025 -4.1629 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.7021 -4.9922 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.4149 -5.4034 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.9889 -3.7488 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
26.9947 -2.9262 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.2853 -2.5122 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.5675 -2.9197 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
25.5636 -3.7456 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.2777 -4.1641 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.8556 -2.5029 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.8605 -1.6780 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
24.1386 -2.9111 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.1157 -5.4163 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 4 2 0
4 5 1 0
5 6 2 0
6 1 1 0
7 8 1 0
7 12 1 0
8 9 1 0
9 10 1 0
10 11 1 0
11 12 1 0
1 7 1 0
7 13 1 6
13 14 1 0
17 18 2 0
15 16 2 0
14 15 1 0
16 17 1 0
18 14 1 0
10 19 1 1
19 20 1 0
20 21 1 0
21 22 2 0
22 23 1 0
23 24 2 0
24 25 1 0
25 26 2 0
26 21 1 0
24 27 1 0
27 28 1 0
27 32 1 0
28 29 1 0
29 30 1 0
30 31 1 0
31 32 1 0
30 33 1 0
33 34 2 0
33 35 1 0
6 36 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 511.02Molecular Weight (Monoisotopic): 510.2034AlogP: 3.69#Rotatable Bonds: 7Polar Surface Area: 69.06Molecular Species: NEUTRALHBA: 7HBD: ┄#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): ┄#RO5 Violations (Lipinski): 1CX Acidic pKa: ┄CX Basic pKa: 6.42CX LogP: 3.62CX LogD: 3.59Aromatic Rings: 3Heavy Atoms: 36QED Weighted: 0.48Np Likeness Score: -0.77
References 1. (2016) Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome p450 inhibition and their method of use, 2. Blass, Benjamin E BE and 18 more authors. 2016-12-01 Design, synthesis, and evaluation of (2S,4R)-Ketoconazole sulfonamide analogs as potential treatments for Metabolic Syndrome. [PMID:27789139 ] 3. Fehl, Charlie C and 5 more authors. 2018-06-14 Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2. [PMID:29792703 ]